Pardes Biosciences, Inc.
PRDSNASDAQHealthcare
$2.18
+$0.02(+0.93%)
Market Cap$135185724
P/E Ratio—
52W High$3.67
52W Low$0.75
Pardes Biosciences, Inc. (PRDS) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · PRDS · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2022-12 | 2021-12 |
|---|---|---|
| Revenue | ||
| Revenue | $0.00B | $0.00B |
| Cost of Revenue | $0.00B | $0.00B |
| Gross Profit | $0.00B | $0.00B |
| Gross Margin %(computed) | — | — |
| Operating Expenses | ||
| R&D Expenses | $0.07B | $0.03B |
| G&A Expenses | $0.03B | $0.01B |
| Total Operating Expenses | $0.10B | $0.04B |
| Operating Income | ($0.10B) | $0.04B |
| Operating Margin %(computed) | — | — |
| Interest Income | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B |
| Income Before Tax | ($0.10B) | $0.00B |
| Income Tax Expense | ($0.00B) | $0.00B |
| Net Income | ($0.09B) | ($0.04B) |
| Net Margin %(computed) | — | — |
| Per Share & EBITDA | ||
| EPS (Basic) | $-1.61 | $-0.68 |
| Wtd Avg Shares | 0.06B | 0.06B |
| EBITDA | ($0.09B) | $0.04B |
| EBITDA Margin %(computed) | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · B
Explore more Pardes Biosciences, Inc. data
About Pardes Biosciences, Inc. (PRDS) Income Statement
Pardes Biosciences, Inc. (PRDS) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2022, PRDS reported revenue of $0.00B, gross profit of $0.00B (gross margin —), and net income of ($0.09B) — a net profit margin of —.
Frequently asked questions
PRDS · 4 questionsPardes Biosciences, Inc. (PRDS) reported revenue of $0.00B for 2022, down —% year-over-year.
PRDS revenuePRDS salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09